Not intended for MEDIA in the United Kingdom and the United States
– The company will provide 54 summaries of its MS portfolio – MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and experimental evobrutinib
– New long-term knowledge and extra concrete evidence characterize the effectiveness and protection of MAVENCLAD®
– New safety data from maVENCLAD® and Rebif® to share, demonstrating that there are no more respiratory viral infections
DARMSTADT, Germany, 3 September 2020 / PRNewswire / – Merck, a leading clinical and technology company, today announced that it will provide knowledge on its experimental and approved sclerosis (SEP) remedies at MSVirtual2020: eighth ACTRIMS-ECTRIMS joint assembly. Merck will provide 54 summaries at the assembly, which will take place virtually from September 11 to 13, 2020, adding new real-world efficacy and safety knowledge from MAVENCLAD® (cladribine tablets) and new safety knowledge for Rebif® (interferon beta-1a).
In addition, knowledge will be presented that experimental evobrutinib appears to be the first and only Crudeon’s tyrosine kinase inhibitor (BTKi) that demonstrates maximum and sustained efficacy for 108 weeks in clinical studies. effect of evobrutinib on the progression of MS.
“The wide variety of studies revealed through this knowledge demonstrates our strategic technique for advancing the MS remedies landscape through new medicines and patient-centered study initiatives,” said Luciano Rossetti, Global Research and Development Manager for Merck’s biopharmaceutical business. “Most of our knowledge provides data on how MAVENCLAD® and Rebif® pose the threat of respiratory viral infections and the effects of COVID-19 on MS patients. This data will help doctors make remedy decisions for their MS patients.
Key insights from MAVENCLAD® (cladribine tablets) include:
Key knowledge of Rebif® (interferon beta-1a) includes:
Key knowledge for evobrutinib includes:
Additional Merck activities at MSVirtual2020:
Today, Merck presented a newsroom for news experts interested in the latest news and developments from the company, merckneurology. com/newsroom, where, among other information, will be available general data on the remedies from Merck MS and video presentations below:
Following the conclusion of MSVirtual2020, Merck will host “Mastering the Neuroscience of Unconscious Bias”, the inaugural virtual occasion of Merck’s I’M IN initiative, an effort of diversity, equity and inclusion presented in February 2019. introduced through the Neurology franchise
Below are the full Merck abstracts accepted for presentation at ACTRIMS-ECTRIMS 2020:
About MAVENCLAD®
MAVENCLAD® is a short-term oral cure that selectively and periodically targets lymphocytes considered to be an integral component of the recurrent MS pathological procedure (MSR). In August 2017, the European Commission (EC) granted marketing authorisation for MAVENCLAD® for the remedy of recurrent multiple sclerosis bureaucracy (MMR) in all 28 European Union (EU) countries, in addition to Norway, Liechtenstein and Iceland, MAVENCLAD® has since been approved in 79 countries, including Canada, Australia and the United States See the relevant prescription data for more details.
The clinical program of cladribine tablets includes:
In the two-year CLARITY study, the most commonly reported maximum adverse occasion (IE) in patients treated with cladribine lymphopenia tablets (26. 7% with cladribine tablets and 1. 8% with placebo). The onset of infections is 48. 3% with cladribine tablets and 42. 5% with placebo, with 99. 1% and 99. 0%, respectively, rated mild to moderate through researchers. Adverse occasions reported in other clinical studies were similar.
About Rebif®
Rebif® (interferon beta-1a) is a under-funded drug used to treat recurrent bureaucracy of sclerosis (MS) and is similar to the interferon beta protein produced through the human body. The efficacy of Rebif® in progressive chronic MS has not been established. Interferon is ideal to help reduce inflammation. The exact mechanism is unknown.
Rebif®, which was approved in Europe in 1998 and the United States in 2002, is registered in more than 90 countries around the world. Rebif® has been shown to stop disability progression, decrease the frequency of relapses, and reduce the activity and mastery of MRI injuries.
Rebif® can be administered with the RebiSmart® electronic self-injection device (not approved in the United States), or with the RebiDose® or RebiSlide ™ manual multi-dose injection pen. Rebif® can also be administered with the Rebiject II® autoinjector or by ready-to-use manual injection pre-filled syringes. These injection devices are not approved in all countries.
In January 2012, the European Commission approved the extension of the Rebif indication® in early sclerosis. The extension of the Rebif® indication was not sent to the United States.
Rebif® not worth being used with caution in patients with a history of depression, liver disease, thyroid and seizures. The most commonly reported side effects are flu-like symptoms, injection site disorders, increased liver enzymes and blood cells. Patients, especially those with depression, epileptic disorders or liver disorders, deserve to talk about treatment with Rebif® with their doctor.
The precise correlation between the effects of MRI and the existing or long-term clinical condition of patients is unknown, as well as the progression of disability.
Rebif® (interferon beta-1a) is approved in the United States for recurrent MS bureaucracy.
About évobrutinib
Evobrutinib (M2951) is in clinical progression to investigate its potential as a remedy for multiple sclerosis (MS). It is a highly selective oral inhibitor of Bruton tyrosine kinase (BTK) that is vital in progression and serves as various immune mobiles, adding B mobiles and macrophages. Evobrutinib is designed to inhibit number one B mobile responses, such as the proliferation and release of antibodies and cytokines, without directly affecting T-mobiles. BtK inhibition is an idea to suppress automatic mobile production. -antibodies, which, according to preclynic research, may be therapeutically useful in certain autoimmune diseases. Evobrutinib is recently under clinical research and is not approved for worldwide use.
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system formula and is the most common non-traumatic debilitating neurological disease in young adults. It is estimated that approximately 2. 3 million people worldwide have MS. Although symptoms may vary,, non-unusual maximum symptoms of MS occur with blurred vision, numbness or tingling in the limbs, and disorders of strength and coordination. The recurrent bureaucracy of MS is the maximum, not unusual.
Merck in neurology and immunology
Merck has a long tradition in the field of neurology and immunology, with extensive experience of R
The company’s portfolio of immunology products focuses on the discovery of new treatments that can modulate key pathogenic mechanisms in chronic diseases such as MS, systemic lupus erythematosus osteoarthritis and psoriasis.
All Merck press releases are distributed by email at the time they can be obtained on Merck’s website. Visit www. merckgroup. com/subscribe to register online, replace your variety, or discontinue this service.
About Merck
Merck, a leading science and generation company, operates in the fields of health, life sciences and functional materials. Approximately 57,000 workers try to make a positive difference in the lives of millions of people each day by creating happier and more sustainable lifestyles. From advancing gene editing technologies and finding unique tactics to treat the most difficult diseases, to device intelligence, business is everywhere. In 2019, Merck achieved sales of 16. 2 billion euros in 66 countries.
Scientific exploration and guilty entrepreneurship have been the key to Merck’s technological and clinical progress. Merck has thrived since its founding in 1668. The circle of founding relatives remains the majority owner of the publicly traded company. Merck owns the global rights to the so-called Merck and the only exceptions are the United States and Canada, where Merck’s lines of business operate under the name EMD Serono in Health, MilliporeSigma in Life Sciences and EMD Performance Materials.
[email protected] 151 1454 2694
Logo: https://mma. prnewswire. com/media/1136775/Merck_Logo. jpg